公开(公告)号：EP1355631B1

公开(公告)日：2007-10-03

申请号：EP01965984.6

申请日：2001-08-17

申请人： Pharmacia Corporation ,  Yamanouchi Pharma Technologies, Inc.

发明人： LE, Trang, T. ,  KARARLI, Tugrul, T. ,  KONTNY, Mark, J. ,  SASTRY, Srikonda, V. ,  NYSHADHAM, Janaki, R. ,  PAGLIERO, Arthur, J., Jr.

IPC分类号： A61K9/20 ,  A61K31/635

CPC分类号： A61K9/0056 ,  A61K9/2077 ,  A61K31/415 ,  A61K31/635

摘要： A process is provided for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug, the process comprising (a) a step of wet granulating the drug together with a binding agent comprising a saccharide of high moldability, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simulatenously to result in formation of granules. The process optionally incorporates means to inhibit agglomeration of the drug, for example addition of a wetting agent. Optionally the process further comprises (c) a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and (d) a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a composition prepared by such a process.

公开(公告)号：EP1355631A2

公开(公告)日：2003-10-29

申请号：EP01965984.6

申请日：2001-08-17

申请人： Pharmacia Corporation ,  Yamanouchi Pharma Technologies, Inc.

发明人： LE, Trang, T. ,  KARARLI, Tugrul, T. ,  KONTNY, Mark, J. ,  SASTRY, Srikonda, V. ,  NYSHADHAM, Janaki, R. ,  PAGLIERO, Arthur, J., Jr.

IPC分类号： A61K9/20 ,  A61K31/635

CPC分类号： A61K9/0056 ,  A61K9/2077 ,  A61K31/415 ,  A61K31/635

摘要： A process is provided for preparing an oral fast-melt composition of a selective cyclooxygenase-2 inhibitory drug, the process comprising (a) a step of wet granulating the drug together with a binding agent comprising a saccharide of high moldability, and (b) a step of blending with the drug a saccharide of low moldability, wherein the above steps (a) and (b) occur in any order or simulatenously to result in formation of granules. The process optionally incorporates means to inhibit agglomeration of the drug, for example addition of a wetting agent. Optionally the process further comprises (c) a step of blending the granules with at least one of a lubricant, a sweetening agent and a flavoring agent to form a tableting blend, and (d) a step of compressing the tableting blend to form oral fast-melt tablets. Also provided is a composition prepared by such a process.